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Venous thrombosis is the third most common cardiovascular disease in the Western 
world after coronary artery disease and stroke [1]. It is a prevalent illness and it occurs 
in 1 per 1000 persons per year and in 1 per 100 people over 75 years old per year 
(source: Dutch Heart Foundation). Venous thrombosis is a serious condition that can 
lead to a life-threatening complication known as pulmonary embolism. Presently used 
treatments for venous thrombosis increase risk of bleeding in patients. Therefore, 
scientific research on the mechanisms of venous thrombosis and the development of 
novel treatment options will be beneficial for thrombosis patients. 
In order to perform research that provides directly applicable results and has a 
notable impact on society, scientific knowledge is needed. The knowledge is 
developed by fundamental research, the purpose of which is to improve our 
understanding of natural phenomena without necessarily finding solutions to practical 
problems. In other words, it is essential to acquire knowledge prior to finding ways 
how to use it for the benefit of society. 
The work described in this thesis is an example of fundamental research. It has 
previously been discovered in population studies that people who have low levels of 
an alternatively spliced variant of fibrinogen γ’ are at higher risk for venous 
thrombosis. Also, it has been shown that this form of fibrinogen specifically binds to 
thrombin exosite II and modulates thrombin activity. Our aim was to understand 
which of thrombin’s functions are affected by fibrinogen γ’, in order to get more 
insight in the association between low levels of fibrinogen γ’ and risk for venous 
thrombosis.  
First, we found that a peptide that resembles the C-terminal end of fibrinogen γ’, 
which contains the thrombin exosite II-binding site, inhibits FV activation by thrombin. 
This, together with its previously described ability to inhibit FVIII activation, underlies 
the ability of fibrinogen γ’ (peptide) to increase APC sensitivity of plasma. This effect is 
important, as APC resistance is the most common risk factor for venous thrombosis in 
Caucasians [2]. Since the causes of APC resistance are manifold, there is no specific 
treatment for this condition. The fibrinogen γ’ peptide does not influence FVa and 
FVIIIa to make them more sensitive to the inactivation by APC. Instead, it inhibits their 
production, making it easier for APC to down-regulate their activity. Therefore, the 
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fibrinogen γ’ peptide could be a universal solution to counteract APC resistance 
irrespective of its cause. 
Antithrombotic medications that are currently used for treatment and prevention of 
thrombotic disorders increase the risk of bleeding, since they interfere with processes 
required for normal hemostasis. It is obvious that new anticoagulants that act on 
different components of the coagulation system are needed. FXI has recently become 
an attractive target for the development of alternative anticoagulant therapies, as 
decreasing its level and activity reduces the risk of venous thrombosis without 
increasing the risk of bleeding [3]. An antisense oligonucleotide decreasing FXI levels 
in a dose-dependent manner has been reported to be effective in reducing the risk of 
postoperative thrombosis without increasing bleeding in a clinical study with 300 
patients [4]. These data support the efficacy and safety of anti-FXI approaches as a 
basis for developing pharmacologic strategies. Similarly, our finding that the 
fibrinogen γ’ peptide inhibits thrombin-mediated FXI activation can also contribute to 
its therapeutic potential. 
The advantage of the peptide compared to the whole fibrinogen γ’ molecule is that 
the peptide has only the effects of binding to the exosite II of thrombin, and not the 
undesired effects of the whole fibrinogen γ’ molecule on fibrin clot structure. In 
addition, since the peptide has the same amino acid sequence as the C-terminal end 
of fibrinogen γ’, it is not foreign to the human body and will not induce immune 
reactions. The fibrinogen γ’ peptide increases plasma APC sensitivity and inhibits FXI 
activation, making it an interesting means for future pharmacological interventions.  
In fact, a company that develops treatment and diagnostic tools based on the specific 
properties of fibrinogen γ’ already exists. Among other products, a next generation 
anticoagulant based on the fibrinogen γ’ C-terminal end peptide, is being developed 
[5].  
We strongly believe that the findings described in this thesis will help advancing the 
development of novel anticoagulants. 
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